In vitro cytotoxicity testing is a mandatory biological safety evaluation required for virtually all patient-contacting medical devices before market approval. Governed internationally by ISO 10993-5 and in China by GB/T 16886.5, the test detects harmful leachable substances released from device materials using cultured mammalian cells. This article explains the applicable standards, sample requirements, testing methods, acceptance criteria, and regulatory applications of in vitro cytotoxicity testing to support NMPA registration, FDA submissions, and EU MDR CE marking.
Technical Overview
In vitro cytotoxicity testing is the foundational biological safety test in the ISO 10993 series of standards for the biological evaluation of medical devices. Specified by ISO 10993-5 (Tests for in vitro cytotoxicity) and its Chinese national counterpart GB/T 16886.5, it is required for essentially every medical device that contacts patients directly or indirectly, regardless of contact duration. The test determines whether a device or its constituent materials release substances that are toxic to living cells.
The test principle is straightforward: cultured mammalian cells, most commonly L929 mouse fibroblasts and alternatively V79 Chinese hamster lung cells or BALB/c 3T3 fibroblasts, are exposed to a test sample or an extract of the sample. After an incubation period of 24 to 48 hours at 37°C in a humidified atmosphere with 5% carbon dioxide, the cells are examined for morphological deterioration, lysis, and reduced viability or proliferation. Toxic leachables such as residual monomers, plasticizers, catalysts, processing aids, sterilant residues, and degradation products manifest as visible cell damage or a measurable loss of metabolic activity.
Results may be assessed qualitatively by microscopy using a 0 to 4 reactivity grading scale, or quantitatively using colorimetric viability assays such as MTT, XTT, WST-8, and neutral red uptake. ISO 10993-5 defines a clear quantitative acceptance threshold: a test article is considered non-cytotoxic when cell viability remains at or above 70% of the blank control.
In vitro cytotoxicity testing offers high sensitivity, short turnaround time, and low cost compared with animal studies, and it embodies the 3Rs principle (replacement, reduction, and refinement) that underpins modern biological safety evaluation. Testing should be performed by accredited third-party laboratories operating under ISO/IEC 17025 quality management systems to ensure data acceptance by regulatory authorities worldwide.
Testing Samples
Finished Medical Devices
The preferred test sample is the medical device in its final finished form, processed and sterilized exactly as intended for clinical use. Final-product testing captures the combined effects of raw materials, manufacturing processes, cleaning agents, additives, and sterilization residuals, providing the most representative assessment of biological safety. Typical examples include syringes, infusion sets, catheters, wound dressings, dental materials, and implantable components.
Raw Materials and Candidate Materials
During product development, raw materials such as polymer resins, pellets, cured elastomers, metal coupons, ceramics, coatings, adhesives, and colorants are frequently screened before tooling investment. Early-stage material screening identifies cytotoxic candidates, supports supplier qualification, and accelerates material substitution decisions while reducing downstream regulatory risk.
Sample Preparation and Extraction Requirements
Sample preparation follows ISO 10993-12. Test articles are extracted in a polar vehicle such as serum-supplemented minimum essential medium (MEM) or D-MEM, physiological saline, or water for injection; non-polar vehicles such as cottonseed oil may be added when the material is expected to release non-polar leachables. Standard extraction ratios are 3 cm² of surface area per milliliter of vehicle for samples thinner than 0.5 mm, 6 cm²/mL for thicknesses of 0.5 mm to 1 mm, 1.25 cm²/mL for thicker samples, and 0.1 to 0.2 g/mL for irregularly shaped solids.
Extraction is conducted under conditions that are exaggerated yet realistic for the intended use of the device: 37°C for 24 hours (the most common condition), 37°C for 72 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour. The selected condition must not alter the physicochemical nature of the material, and extracts are applied to cell cultures promptly after preparation.
Testing Items
A comprehensive in vitro cytotoxicity evaluation may include the following endpoints, selected according to ISO 10993-5 and the intended use of the device:
- Cell morphology assessment: observation of rounding, detachment, lysis, vacuolization, and intracellular granulation under light microscopy, graded 0 (none) to 4 (severe)
- Cell viability: quantitative measurement of metabolic activity using MTT, XTT, WST-1, or WST-8 colorimetric assays read spectrophotometrically at 570 nm
- Neutral red uptake: assessment of lysosomal integrity based on dye accumulation in living cells
- Cell proliferation and growth inhibition: determination of population doubling and growth rate relative to controls
- Membrane integrity: detection of lactate dehydrogenase (LDH) release from damaged cells
- Colony forming efficiency: evaluation of the reproductive capacity of individual cells after exposure
For most regulatory submissions, the combination of qualitative morphological grading plus a quantitative MTT viability assay on L929 cells satisfies the requirements of ISO 10993-5 and GB/T 16886.5.
Testing Methods
Extract Test (Elution Method)
The extract test is the most widely applied approach and is suitable for nearly all device categories. The material extract is applied to a confluent monolayer of L929 cells cultured in MEM with serum, and the cells are incubated for 24 to 48 hours at 37°C with 5% carbon dioxide. The elution method is particularly appropriate for devices with substantial extractable profiles, such as polymeric components, tubing sets, and fluid-path packaging systems.
Direct Contact Test
In the direct contact method, a sterile sample is placed directly onto the cell monolayer, allowing leachable substances to diffuse into the culture medium immediately adjacent to the cells. The method is highly sensitive and is best suited for low-density materials and devices that contact tissue surfaces. Care is taken to minimize mechanical injury from sample weight; a small test specimen and, where necessary, a spacer are used to control physical pressure on the cells.
Agar Diffusion Test (Agar Overlay)
In this indirect contact method, cells are covered with a thin layer of nutrient agar containing neutral red, and the test sample is placed on the agar surface. Toxic substances diffuse through the agar and affect the underlying cells, which are then scored for zone extent and degree of lysis. The agar overlay is well suited to high-density materials such as elastomeric closures and dense polymer sheets whose weight would damage cells in direct contact.
Quantitative Viability Assays
Quantitative methods provide objective, statistically evaluable results. In the MTT assay, mitochondrial dehydrogenases in viable cells reduce the yellow tetrazolium salt MTT to purple formazan crystals, which are solubilized and quantified at 570 nm. Percentage viability is calculated as the absorbance of treated cells relative to the blank control, and dose-response relationships can be established by testing serial dilutions of the extract, for example 25%, 50%, and 100% concentrations.
Evaluation Criteria and Result Interpretation
Under ISO 10993-5, qualitative reactivity of Grade 0 (none) or Grade 1 (slight) generally indicates that the test article meets the requirement, Grade 2 (mild) reactivity typically prompts confirmatory quantitative testing, and Grades 3 to 4 (moderate to severe) indicate cytotoxicity. For quantitative assays, cell viability of 70% or greater relative to the blank control demonstrates that the test article has no cytotoxic potential. Positive controls such as zinc sulfate or a nonionic surfactant and negative controls such as high-density polyethylene are included in every test run to verify system sensitivity and validity.
Applications
In vitro cytotoxicity test reports issued by accredited third-party laboratories are essential technical documents for regulatory submissions worldwide, including NMPA device registration in China, U.S. FDA 510(k) and PMA submissions, EU MDR CE technical documentation, and registrations in Japan, South Korea, Canada, and Brazil. The test is a mandatory element of the biological evaluation plan defined by ISO 10993-1 within the risk management framework of ISO 14971.
Typical product categories that require in vitro cytotoxicity testing include:
- Disposable sterile devices: syringes, infusion sets, blood collection tubes, intravenous catheters, and urethral catheters
- Implantable devices: orthopedic implants, dental implants and restorations, cardiovascular stents, and delivery systems
- Wound care products: dressings, hydrogels, absorbable hemostatic materials, and tissue adhesives
- Blood-contacting devices: dialyzers, blood bags, oxygenators, and extracorporeal circuit tubing
- Topical and mucosal contact products: contact lenses, condoms, surgical gloves, gowns, and drapes
- Materials and components: polymer resins, adhesives, coatings, inks, and pharmaceutical packaging evaluated to the relevant pharmacopoeial in vitro reactivity requirements
Beyond regulatory submission, the test supports research and development screening, supplier and material change evaluation, sterilization method validation, residual ethylene oxide assessment, and periodic quality control, forming the first line of biological risk control throughout the product lifecycle.
FAQ
Which standards govern in vitro cytotoxicity testing for medical devices?
The primary standard is ISO 10993-5 (Biological evaluation of medical devices, Part 5: Tests for in vitro cytotoxicity), adopted in China as GB/T 16886.5. Sample preparation follows ISO 10993-12, and overall test selection is guided by ISO 10993-1. Pharmaceutical packaging materials are commonly evaluated to the corresponding pharmacopoeial in vitro biological reactivity method, and additional materials-level guidance is available from ASTM standards.
What samples and sample quantities are needed?
The final device in its sterilized, ready-to-use condition is preferred. Depending on geometry, laboratories typically require several grams of material or a surface area sufficient to achieve the standard extraction ratio of 3 cm²/mL, for example 60 cm² for a 20 mL extraction. Samples must be handled aseptically or sterilized by the intended production method before submission.
How long does the test take?
A standard qualitative plus MTT quantitative test on L929 cells generally requires 10 to 15 working days from sample receipt, including cell culture preparation, 24 to 72 hour extraction, 24 to 48 hour exposure, and reporting. Dose-response studies and failure investigations may extend the timeline.
What is the pass criterion?
For quantitative tests, cell viability must be at least 70% of the blank control for the sample to be judged non-cytotoxic. For qualitative microscopic evaluation, reactivity no greater than Grade 1 (slight) is generally acceptable, while Grade 2 (mild) reactivity should be confirmed with a quantitative method before drawing conclusions.
Why is the L929 cell line used most frequently?
L929 mouse fibroblasts are an established, well-characterized continuous cell line recommended in ISO 10993-5. They grow reliably in monolayer culture, respond reproducibly to cytotoxic leachables, and are accepted by regulatory authorities worldwide, making them the default choice for medical device testing. V79 and BALB/c 3T3 cells are acceptable alternatives when scientifically justified.
Is cytotoxicity testing mandatory for every medical device?
Yes, in vitro cytotoxicity is a baseline test for essentially all devices that contact patients directly or indirectly, per the test selection matrix in ISO 10993-1. It is the single most frequently requested biological test and is mandatory for NMPA registration, FDA clearance, and EU MDR conformity assessment of patient-contacting devices.
What should be done if a sample fails the test?
A failing result should trigger a structured investigation: verification of test validity through controls, chemical characterization of leachables per ISO 10993-18, review of raw materials, processing aids, cleaning agents, and sterilization residuals, and toxicological risk assessment per ISO 10993-17. Material substitution, process optimization, or improved post-cleaning typically resolves cytotoxicity, and retesting confirms the effectiveness of the corrective action.